SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Emberton M, Andriole GL, De La Rosette J et al. BPH. A progressive disease of the ageing male. Urology 2003; 61: 267 73
  • 2
    Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 4817
  • 3
    Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990; 16: 25361
  • 4
    Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595600
  • 5
    Arrighi HM, Metter EJ, Guess HA, Fozard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991; 38 (Suppl. 1): 48
  • 6
    Wright EJ, Fang J, Metter EJ et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging. J Urol 2002; 167: 24848
  • 7
    Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study group. Urology 1999; 53: 47380
  • 8
    Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride vs placebo. Urology 1999; 54: 6629
  • 9
    Marberger JM, Andersen JR, Nickel JC et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 563 8
  • 10
    Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficiency and safety study. J Urol 2000; 163: 1320
  • 11
    Tenover LJ, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigative Study Group. Clin Ther 1997; 19: 24358
  • 12
    Eckhardt MD, Van Venrooij GE, Van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol 2001; 166: 5638
  • 13
    Jacobsen SJ, Guess HA, Panser L et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med 1993; 2: 72935
  • 14
    Bruskewitz RC, Reda DJ, Wasson JH, Barrett L, Phelan M. Testing to predict outcome after transurethral resection of the prostate. J Urol 1997; 157: 1304 8
  • 15
    Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs co-operative study. J Urol 1998; 160: 126
  • 16
    McConnell JD, Bruskewitz R, Walsh PC et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 55763
  • 17
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 43441
  • 18
    Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995a; 33 (Suppl. 4): AS14555
  • 19
    Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research. How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770 4
  • 20
    Girman CJ, Epstein RS, Jacobsen SJ et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 82531
  • 21
    Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428 36
  • 22
    Sagnier PP, MacFarlane G, Teillac P et al. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995; 153: 66973
  • 23
    Garraway WM, Russell EB, Lee RJ et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J General Pract 1993; 43: 31821
  • 24
    Byrnes CA, Morton AS, Liss CL et al. Efficacy, tolerability, and effect on health specific quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study. CUSP Investigators. Community based Study of Proscar. Clin Ther 1995; 17: 95669
  • 25
    De La Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167: 17349